-
公开(公告)号：US20230220063A1
公开(公告)日：2023-07-13
申请号：US16624130
申请日：2018-06-22
申请人： NOVARTIS AG
发明人： Monica LIGUEROS-SAYLAN , Patrice MATCHABA , Tom THUREN , Paul RIDKER , Peter LIBBY , Penelope OTTEWELL , Yang Yi LAU , Margaret DUGAN
IPC分类号： C07K16/24 , A61K39/00 , A61P35/00 , A61K9/00 , G01N33/574
CPC分类号： C07K16/245 , A61K9/0019 , A61K39/00114 , A61P35/00 , G01N33/57423 , A61K31/282 , A61K2039/54 , A61K2039/82 , A61K2039/86 , A61K2039/505 , A61K2039/545 , A61K2039/828 , A61K2039/836 , A61K2039/868
摘要： Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.
-
公开(公告)号：US20170253633A1
公开(公告)日：2017-09-07
申请号：US15445461
申请日：2017-02-28
发明人： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC分类号： C07K7/08 , C07K16/18 , G01N33/68 , A61K35/17 , A61K39/00 , C12N15/115 , C07K7/06 , C07K14/725
CPC分类号： C07K7/08 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/80 , A61K2039/804 , A61K2039/812 , A61K2039/82 , A61K2039/828 , A61K2039/836 , A61K2039/844 , A61K2039/852 , A61K2039/86 , A61K2039/868 , A61K2039/876 , A61K2039/884 , A61K2039/892 , C07K7/06 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K2319/00 , C12N15/115 , C12N2310/16 , G01N33/6893 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US12084522B2
公开(公告)日：2024-09-10
申请号：US17339157
申请日：2021-06-04
发明人： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K16/18 , A61K35/17 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/725 , C12N15/115 , G01N33/68 , A61K35/12
CPC分类号： C07K7/08 , A61K35/17 , A61K39/0011 , C07K7/06 , C07K14/4748 , C07K14/7051 , C07K16/18 , C12N15/115 , G01N33/6893 , A61K2035/124 , A61K2039/5154 , A61K2039/80 , A61K2039/804 , A61K2039/812 , A61K2039/82 , A61K2039/828 , A61K2039/836 , A61K2039/844 , A61K2039/852 , A61K2039/86 , A61K2039/868 , A61K2039/876 , A61K2039/884 , A61K2039/892 , C07K2319/00 , C12N2310/16 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
4.发明授权公开(公告)号：US11771759B2
公开(公告)日：2023-10-03
申请号：US16491550
申请日：2018-01-24
申请人： FUDAN UNIVERSITY
发明人： Bin Wang , Weidong Zhao , Gan Zhao , Yiwei Zhong
IPC分类号： A61K39/29 , A61P35/00 , A61K39/00 , A61K39/09 , A61K39/39 , C12N7/00 , C07K14/52 , C07K14/535 , C07K14/565
CPC分类号： A61K39/29 , A61K39/001157 , A61K39/001186 , A61K39/001193 , A61K39/092 , A61K39/39 , A61P35/00 , C07K14/52 , C07K14/535 , C07K14/565 , C12N7/00 , A61K2039/545 , A61K2039/55522 , A61K2039/804 , A61K2039/812 , A61K2039/868 , A61K2039/884 , A61K2039/892 , C12N2730/10011 , C12N2730/10034 , C12N2730/10134
摘要： An immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic phar-maceutical composition comprising at least an antigen and the above-mentioned immune enhancers is disclosed. A preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition are also disclosed. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.
-
公开(公告)号：US20190241659A1
公开(公告)日：2019-08-08
申请号：US16184251
申请日：2018-11-08
申请人： MEDIMMUNE, LLC
发明人： JOHN MUMM , YUE WANG , RYAN GILBRETH , RONALD HERBST , SCOTT HAMMOND , MICHAEL OBERST , GODFREY JONAH RAINEY , SIMON DOVEDI , JONATHAN SEAMAN , MICHELLE TURNHAM
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , A61K45/06
CPC分类号： C07K16/2818 , A61K39/12 , A61K39/39 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2039/505 , A61K2039/572 , A61K2039/585 , A61K2039/868 , A61P31/20 , A61P35/00 , C07K14/70575 , C07K16/2827 , C07K2317/31 , C07K2317/52 , C07K2317/53 , C07K2317/55 , C07K2317/622 , C07K2317/77 , C07K2317/94 , C07K2319/00 , C12N2710/16134
摘要： Provided herein are bispecific fusion proteins and methods of using the bispecific fusion proteins for treating cancer.
-
公开(公告)号：US12103984B2
公开(公告)日：2024-10-01
申请号：US17333945
申请日：2021-05-28
发明人： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K16/18 , A61K35/17 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/725 , C12N15/115 , G01N33/68 , A61K35/12
CPC分类号： C07K7/08 , A61K35/17 , A61K39/0011 , C07K7/06 , C07K14/4748 , C07K14/7051 , C07K16/18 , C12N15/115 , G01N33/6893 , A61K2035/124 , A61K2039/5154 , A61K2039/80 , A61K2039/804 , A61K2039/812 , A61K2039/82 , A61K2039/828 , A61K2039/836 , A61K2039/844 , A61K2039/852 , A61K2039/86 , A61K2039/868 , A61K2039/876 , A61K2039/884 , A61K2039/892 , C07K2319/00 , C12N2310/16 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11673917B2
公开(公告)日：2023-06-13
申请号：US16671981
申请日：2019-11-01
发明人： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K7/08 , C07K16/18 , A61K39/00 , C07K14/47 , C07K14/725 , C07K7/06 , G01N33/68 , C12N15/115 , A61K35/17 , A61K35/12
CPC分类号： C07K7/08 , A61K35/17 , A61K39/0011 , C07K7/06 , C07K14/4748 , C07K14/7051 , C07K16/18 , C12N15/115 , G01N33/6893 , A61K2035/124 , A61K2039/5154 , A61K2039/80 , A61K2039/804 , A61K2039/812 , A61K2039/82 , A61K2039/828 , A61K2039/836 , A61K2039/844 , A61K2039/852 , A61K2039/86 , A61K2039/868 , A61K2039/876 , A61K2039/884 , A61K2039/892 , C07K2319/00 , C12N2310/16 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
8.发明申请METHOD OF TREATMENT USING FOLATE CONJUGATES AND TYROSINE KINASE INHIBITORS 审中-公开使用纤维结合物和酪氨酸激酶抑制剂治疗的方法公开(公告)号：US20160166679A1
公开(公告)日：2016-06-16
申请号：US14966530
申请日：2015-12-11
发明人： Philip S. Low , Nimalka A. Bandara
IPC分类号： A61K39/385 , A61K31/403 , A61K31/4439 , A61K39/39 , A61K47/48
CPC分类号： A61K39/385 , A61K31/404 , A61K31/4439 , A61K39/0005 , A61K45/06 , A61K47/551 , A61K47/643 , A61K47/646 , A61K51/0459 , A61K51/0497 , A61K2039/545 , A61K2039/55577 , A61K2039/55583 , A61K2039/585 , A61K2039/6012 , A61K2039/6081 , A61K2039/804 , A61K2039/86 , A61K2039/868 , A61K2300/00
摘要： The invention relates to a method of treating a cancer, the method comprising the steps of administering to a patient an immunogen conjugate, administering to the patient a folate conjugate comprising a folate linked to a hapten, and administering to the patient a tyrosine kinase inhibitor.
摘要翻译： 本发明涉及一种治疗癌症的方法，所述方法包括以下步骤：向患者施用免疫原缀合物，向患者施用包含与半抗原连接的叶酸的叶酸缀合物，以及向患者施用酪氨酸激酶抑制剂。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.016 秒)
